RESEARCH ARTICLE

 View Article Online
 View Journal | View Issue

 Cite this: *Med. Chem. Commun.*,
 2019, 10, 89

Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus†

 Yongshi Yu,^{†ab} Tazeem,^{†bc} Zhichao Xu,^b Liaoqi Du,^a Mengyu Jin,^b
 Chune Dong,^{id b} Hai-Bing Zhou^{id *b} and Shuwen Wu^{*a}

Influenza A virus is an enveloped negative single-stranded RNA virus that causes febrile respiratory infection and represents a clinically challenging threat to human health and even lives worldwide. Even more alarming is the emergence of highly pathogenic avian influenza (HPAI) strains such as H5N1, which possess much higher mortality rate (60%) than seasonal influenza strains in human infection. In this study, a novel series of heteroaromatic-based benzenesulfonamide derivatives were identified as M2 proton channel inhibitors. A systematic investigation of the structure–activity relationships and a molecular docking study demonstrated that the sulfonamide moiety and 2,5-dimethyl-substituted thiophene as the core structure played significant roles in the anti-influenza activity. Among the derivatives, compound **11k** exhibited excellent antiviral activity against H5N1 virus with an EC₅₀ value of 0.47 μM and selectivity index of 119.9, which are comparable to those of the reference drug amantadine.

 Received 23rd September 2018,
 Accepted 23rd November 2018

DOI: 10.1039/c8md00474a

rsc.li/medchemcomm

Influenza is a common and serious infectious respiratory disease caused by influenza viruses belonging to the *Orthomyxoviridae* family.¹ Despite decades of surveillance and interventions, seasonal influenza viruses continue to cause epidemics around the world each year. According to the World Health Organization, seasonal influenza epidemics result in 3–5 million flu patients and 290 000 to 650 000 deaths worldwide each year.² Due to its higher antigenic mutation, influenza A (flu A) virus is a greater threat to human health compared to flu B and C strains. Five flu A pandemics have occurred in the past 100 years: 1918 H1N1 (Spanish flu), 1957 H2N2 (Asian flu), 1968 H3N2 (Hong Kong flu), 2005 H5N1 (Bird flu) and 2009 H1N1 (Swine flu).^{3–8} Among them, the 1918 pandemic was the most severe, leading to a catastrophic 50 million deaths globally.^{3,9–11} Worryingly, highly pathogenic avian influenza (HPAI) viruses have recently emerged, including H5N1 (ref. 12–15) and H7N9.^{16,17} These viruses possess higher mortality compared to seasonal influenza viruses.¹⁸ HPAI H5N1 flu strains have

been shown to be transmissible among humans after acquiring only one or a few mutations, generating considerable concern among researchers.^{14,19,20} Although vaccines and antiviral agents are essential measures for influenza treatment, anti-influenza agents seem to be more effective at preventing highly contagious influenza infections due to the frequent variation of influenza virus through antigenic drift and antigenic shift.⁸ Currently, two classes of anti-influenza drugs are applied for the prophylaxis and treatment of influenza infection (Fig. 1): M2 proton channel inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir, zanamivir and peramivir). However, the drug resistance of H5N1 viral strains limits the usable clinical range

Fig. 1 Approved anti-influenza drugs for influenza treatment.

^a State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China. E-mail: shuwenwu@hotmail.com

^b Hubei Province Key Laboratory of Allergy and Immunology, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China. E-mail: zhouhb@whu.edu.cn

^c Department of Chemistry, Shia P. G. College (University of Lucknow), Lucknow Uttar Pradesh 226020, India

† Electronic supplementary information (ESI) available: NMR spectra of **11–12**. See DOI: 10.1039/c8md00474a

‡ These two authors contributed equally to this work.

of these drugs, making the identification of novel anti-influenza agents imperative.^{21–24}

As a consequence, some small molecules that inhibit influenza A H5N1 virus have been created through the structural modification of approved anti-influenza drugs or using the hit-and-lead discovery strategy (Fig. 2).

In 2010, based on high-throughput screening, Severson and coworkers reported quinazolinone analogues as novel inhibitors; compound **1** exhibited an excellent EC_{50} value of 0.032 μ M for both H5N1 and H1N1 viruses.²⁵ In 2011, Liu and co-workers found that 3-fluoro-*N*-(2-(piperidin-1-yl)ethyl)-5-(trifluoromethyl)benzamide hydrochloride (**2**, Fig. 2) could inhibit HPAI H5N1 virus infection by blocking viral entry with an IC_{50} value of 27.03 μ M.²⁶ More recently, polyphenol (**3**, Fig. 2) was identified as entry inhibitor against H5N1 virus with an EC_{50} value of 1.78 μ M, superior to that of the reference drug amantadine.²⁷ In 2017, Liu's group discovered a series of oligo-thiophene compounds as HA inhibitors that act by inhibiting the membrane fusion between the H5N1 virus and the endosome of the host cell. The most potent inhibitor (**4**, Fig. 2) displayed good anti-H5N1 activity with an IC_{50} value of 0.029 μ M.²⁸ In the same year, our group developed furan-carboxamide derivatives as novel inhibitors of H5N1 influenza A virus. The most potent compound (**5**, Fig. 2) showed low-micromolar activity against H5N1 virus with an EC_{50} value of 1.25 μ M, which was comparable with reference drug amantadine.²⁹ The systematic investigation of the structure-activity relationships (SARs) of furan-carboxamide analogues indicated that heteroaromatic groups (*e.g.*, furan and thiophene moieties) and sulfur atoms played significant roles in the inhibition of H5N1 virus. Moreover, furan-carboxamide derivatives containing *para*-substituents on the phenyl rings showed more potent anti-H5N1 activity than those with *meta*- or *ortho*-substituents on the phenyl rings. A molecular docking investigation of this series of furan-carboxamide analogues indicated that they cannot efficiently interact with the M2 protein cavity due to the long linker. Our long-term aim is the development of antivirals with better inhibitory potency and fewer side effects than currently used drugs;^{29–33} hence, to develop novel heteroaromatic-based benzenesulfonamide compounds as anti-influenza A/H5N1 agents, an attempt was made to modify the structural features of furan-

carboxamide derivatives by shortening the linker length and transforming the heteroaromatic core structure (Scheme 1).

Results and discussion

Chemistry

The synthesis of the designed heteroaromatic-based benzenesulfonamide derivatives is shown in Scheme 2. All designed compounds were synthesized *via* the sulfonylation reaction of substituted benzenesulfonyl chloride analogues with diversified amines. Most amines were formed starting from corresponding carboxylic acid **6**, as shown in Scheme 2. First, heteroaromatic formic acid **6** reacted with thionyl chloride to produce aromatic formyl chloride (**7**). Formamide **8** was then formed *via* the amination reaction of **7** and ammonium hydroxide in the presence of dichloromethane (DCM). Next, the key amine **9** was synthesized through reduction reaction in the presence of lithium aluminum hydride followed by the sulfonylation reaction to generate the final products (**11–12**) in 20%–60% yields.

Structure-activity relationship (SAR) studies

All synthesized novel heteroaromatic-based arylsulfonamide compounds were tested for anti-influenza activity against both amantadine-sensitive H5N1 virus and amantadine-resistant H5N1 virus using plaque reduction assays in MDCK cells. The reference anti-influenza drugs amantadine (AMD) and oseltamivir phosphate were used for comparison. The results of this extensive biological evaluation are described in Tables 1 and 2. As a global observation, the heteroaromatics as core structures played significant roles in the activity against amantadine-sensitive H5N1 virus. Originally, the designed heteroaromatic-based benzenesulfonamide compound **11a** containing furan as a core structure and 4- NO_2 as the R substituent showed good potency against H5N1 virus (EC_{50} = 1.06 μ M; Table 1, entry 1). To explore the effects of R substituents on the anti-influenza activity, compounds **11b–e** were synthesized by introducing electron-withdrawing groups (4-CN, 4-F, 4-Cl and 4-Br) (Table 1, entries 2–5).

Fig. 2 Structures of known small-molecule inhibitors of H5N1 influenza A virus.

Scheme 1 Strategy for designing heteroaromatic-based benzenesulfonamide derivatives as novel inhibitors of H5N1 influenza A virus.

Scheme 2 Synthetic route for heteroaromatic-based benzenesulfonamide derivatives. Reagents and conditions: (a) SOCl_2 , toluene, reflux; (b) NH_4OH , DCM, rt; (c) LiAlH_4 , THF, reflux; (d) Et_3N , DCM, rt.

Unfortunately, analogues **11b–e** all displayed decreased inhibitory potency. Considering that sulfur and oxygen atoms have similar chemical properties, bioisostere analogues **11g–k** were synthesized (Table 1, entries 7–11). Surprisingly, we found that all compounds displayed superior anti-H5N1 activity with the exception of compound **11i** (containing 4-F), which showed no inhibition potency. Among **11g–k**, the most

potent analogue **11k** exhibited an EC_{50} value of $0.47 \mu\text{M}$, comparable with those of the reference drugs amantadine and oseltamivir phosphate (Table 1, entries 11 vs. 15 and 16). We also explored the influence of other heteroaromatic core structures on the anti-influenza activity in the presence of 4- NO_2 as the R substituent. We found that analogue **11f** showed dramatically decreased inhibition potency when a furan moiety was the core structure (Table 1, entries 1 vs. 6). Moreover, introducing a thiophene or 2-chloro-thiophene moiety as the core structure also resulted in slightly decreased anti-influenza activity (Table 1, entries 1 and 12–14). Meanwhile, we tested the antiviral activity against amantadine-resistant H5N1 virus in MDCK cells. Unfortunately, these benzenesulfonamide analogues showed no inhibition potency (Table 1, entries 1–14).

Next, we further investigated the SAR when using a benzothiophene moiety as the core structure. Initially, we synthesized compound **12a** with a C3-substituted benzothiophene moiety as the core structure and 4- NO_2 as the R substituent. Interestingly, **12a** maintained potency against the amantadine-sensitive H5N1 virus when the benzothiophene

Table 1 Anti-H5N1 activities of furan- or thiophene-based benzenesulfonamide derivatives **11a–n** in MDCK cells^a

Entry	Cmpd	Core structure	R	EC_{50} (μM) ^b AMD-sensitive H5N1	EC_{50} (μM) ^c AMD-resistant H5N1	CC_{50} (μM) ^d	SI^e
1	11a		4- NO_2	1.06 ± 0.26	NA	$>152.10 \pm 40.60$	>143.5
2	11b		4-CN	4.03 ± 1.62	NA	105.39 ± 22.04	26.1
3	11c		4-F	8.08 ± 1.84	NA	138.01 ± 36.00	17.1
4	11d		4-Cl	1.37 ± 0.27	NA	55.71 ± 16.34	40.7
5	11e		4-Br	1.80 ± 0.52	NA	29.63 ± 10.75	16.5
6	11f		4- NO_2	47.19 ± 17.25	NA	>236.30	>5.0
7	11g		4- NO_2	1.29 ± 0.43	NA	>204.36	>158.4
8	11h		4-CN	0.62 ± 0.098	NA	>217.69	>351.1
9	11i		4-F	NA ^f	NA	— ^g	— ^h
10	11j		4-Cl	0.70 ± 0.16	NA	52.88 ± 14.56	75.5
11	11k		4-Br	0.47 ± 0.11	NA	56.35 ± 14.43	119.9
12	11l		4- NO_2	1.47 ± 0.77	NA	138.77 ± 28.83	94.4
13	11m		4- NO_2	1.91 ± 0.94	NA	133.41 ± 27.82	69.8
14	11n		4- NO_2	70.05 ± 25.87	NA	127.72 ± 28.85	1.8
15	AMD			0.43 ± 0.13	NA	>100.00	>235.3
16	Oseltamivir phosphate			0.39 ± 0.10	0.34 ± 0.02	>163.26	>418.6

^a All data were obtained from at least three independent experiments. ^b EC_{50} , concentration that effectively inhibited amantadine-sensitive H5N1 virus plaque formation by 50%. ^c EC_{50} , concentration that effectively inhibited amantadine-resistant H5N1 virus plaque formation by 50%. ^d CC_{50} , concentration that inhibited cell growth by 50% compared with control cultures. ^e Selectivity index (SI) was determined for effective compounds by dividing CC_{50} by EC_{50} (amantadine-sensitive H5N1 virus). ^f NA: no activity ($\text{EC}_{50} > 100 \mu\text{M}$). ^g —: no detection. ^h —: no selectivity index.

Table 2 Anti-H5N1 activities of benzothiophene-based benzenesulfonamide derivatives **12a–s** in MDCK cells^a

Core

Entry	Cmpd	Core structure	R	EC ₅₀ ^b (μM) AMD-sensitive H5N1	EC ₅₀ ^c (μM) AMD-resistant H5N1	CC ₅₀ ^d (μM)	SI ^e
1	12a		4-NO ₂	1.38 ± 0.29	NA	>191.45	>138.7
2	12b		4-CN	20.28 ± 8.34	NA	122.41 ± 32.59	6.0
3	12c		4-F	3.42 ± 0.81	NA	98.64 ± 29.25	28.8
4	12d		4-Cl	1.98 ± 0.68	NA	69.56 ± 15.39	35.1
5	12e		4-Br	7.22 ± 1.60	NA	87.11 ± 21.71	12.1
6	12f		4-CF ₃	38.56 ± 14.73	NA	94.78 ± 14.27	2.5
7	12g		4-Me	10.49 ± 3.78	NA	>210.13	>20.0
8	12h		2-F	NA ^f	NA	— ^g	— ^h
9	12i		3-F	NA	NA	—	—
10	12j		4-COCH ₃	12.04 ± 3.85	NA	>193.09	>16.0
11	12k		4-NO ₂	49.97 ± 14.87	NA	>191.45	>3.8
12	12l		4-CN	NA	NA	—	—
13	12m		4-F	NA	NA	—	—
14	12n		4-Cl	NA	NA	—	—
15	12o		4-Br	40.70 ± 12.11	NA	>174.47	>4.3
16	12p		4-CF ₃	44.83 ± 16.51	NA	>179.60	>4.0
17	12q		4-Me	41.96 ± 13.74	NA	>210.13	>5.0
18	12r		2-F	NA	NA	—	—
19	12s		3-F	NA	NA	—	—
20	AMD			0.43 ± 0.13	NA	>100.00	>235.3
21	Oseltamivir phosphate			0.39 ± 0.10	0.34 ± 0.02	>163.26	>418.6

^a All data were obtained from at least three independent experiments. ^b EC₅₀, concentration that effectively inhibited amantadine-sensitive H5N1 virus plaque formation by 50%. ^c EC₅₀, concentration that effectively inhibited amantadine-resistant H5N1 virus plaque formation by 50%. ^d CC₅₀, concentration that inhibited cell growth by 50% compared with control cultures. ^e Selectivity index (SI) was determined for the effective compounds by dividing CC₅₀ by EC₅₀ (amantadine-sensitive H5N1 virus). ^f NA: no activity (EC₅₀ > 100 μM). ^g —: no detection. ^h —: no selectivity index.

moiety was the core structure, indicating that our hypothesis was rational (Table 1, entries 7, 12–13 vs. Table 2, entry 1).

To further explore the influence of the R substituent on the antiviral activity, we designed and synthesized compounds **12b–g** and **12j** containing electron-withdrawing groups (4-CN, 4-F, 4-Cl, 4-Br, 4-CF₃ and 4-COCH₃) and an electron-donating group (4-Me), respectively (Table 2, entries 2–7 and 10). All compounds displayed inferior activity against amantadine-sensitive H5N1 virus compared to compound **12a**; in particular, the potency of analogue **12f** was approximately 28 times lower than that of **12a**, likely due to the stronger electron-withdrawing property of the 4-CF₃ group (Table 2, entries 1 vs. 6). Meanwhile, analogues **12k–q** were synthesized to study the effect of the C2-substituted benzothiophene moiety as a core structure on the biological activity. These analogues all exhibited over 30-fold decreased potency compared to the corresponding analogues **12a–g** containing C3-substituted benzothiophene moiety as the core structure (Table 2, entries 1–7 and 11–17). We also synthesized analogues **12h–i** and **12r–s** to study the anti-H5N1 activity of analogues containing *ortho*- and *meta*-substituents as R groups. The biological results indicated no inhibitory activity against amantadine-sensitive H5N1 virus, showing that a *para*-substituent as the R group is important for the anti-influenza

activity (Table 2, entry 3 vs. 8–9 and entry 13 vs. 18–19), which is consistent with our prediction. Among benzothiophene-based benzenesulfonamide derivatives, the C3-substituted compound **12a** displayed potent antiviral activity against amantadine-sensitive H5N1 virus with an EC₅₀ of 1.38 μM (Table 2, entry 1). Next, we evaluated the activity against amantadine-resistant H5N1 virus in MDCK cells. Unfortunately, these benzothiophene-based benzene-sulfonamide derivatives displayed no potency (Table 2, entries 1–19).

Fig. 3 intuitively shows that the 2,5-dimethyl-substituted thiophene moiety was a more potent core structure than the 2,5-dimethyl-substituted furan moiety or benzo-thiophene moiety in terms of anti-influenza activity against amantadine-sensitive H5N1 virus (Fig. 3A and B). Furthermore, the *para*-substituent was superior to the *meta*- or *ortho*-substituent as an R group in terms of activity.

The anti-proliferative activities of the synthesized compounds against MDCK cells were also evaluated to monitor potential cytotoxic effects. As expected, none of the heteroaromatic-based benzenesulfonamide derivatives obviously inhibited the growth of MDCK cells at a concentration of 50 μM, with the exception of compound **11e**, consolidating the safety of this series of compounds (Tables 1 and 2).

Fig. 3 Graphical representation of the effects of the core structure and R substituent of heteroaromatic-based benzenesulfonamide compounds on activity against amantadine-sensitive H5N1 virus in MDCK cells. A) The effects of 2,5-dimethylfuran or 2,5-dimethylthiophene moiety as core structure and R substituent of compounds **11a–e** and **11g–k** on antiviral activity; B) the effects of benzothiophene as core structure and R substituent of compounds **12a–g** and **12k–q** on antiviral activity.

Preliminary mechanistic studies based on a time-course experiment with compound **11k** and reference drugs amantadine and favipiravir (T-705) demonstrated that the novel heteroaromatic-based benzenesulfonamide derivatives prevented early-stage virus replication (Fig. 4). Similar to the M2 proton channel inhibitor amantadine, compound **11k** likely blocked channel function to inhibit the uncoating of the viral RNPs.³⁴

To further explore the possible drug target of this series of novel heteroaromatic-based benzenesulfonamide derivatives, we performed a yeast growth restoration assay.^{35–38} The M2 proton channel inhibitor amantadine and neuraminidase (NA) inhibitor oseltamivir were included as reference drugs. The yeast toxicities of the heteroaromatic-based benzenesulfonamide derivatives were also evaluated to eliminate the contribution of toxic effects. As shown in Table 3, this series of compounds exhibited good potency against WT M2 and

displayed little yeast toxicity in the yeast growth restoration assay, which was almost consistent with the anti-H5N1 activity results in MDCK cells (Table 3 vs. Tables 1 and 2). Moreover, compounds **11a**, **11h**, **11j** and **11k** showed excellent activity against WT M2 in comparison to amantadine (Table 3, entries 1, 8, 10–11 and 34). In contrast, the NA inhibitor oseltamivir showed no inhibitory potency against WT M2 (Table 3, entry 35). Thus, the heteroaromatic-based benzenesulfonamide analogues inhibited WT M2 expression in yeast similarly to the M2 inhibitor amantadine, demonstrating that M2 protein was the drug target of this series of compounds. Unfortunately, these novel heteroaromatic-based benzenesulfonamide derivatives displayed no potency against mutant S31N/V27A M2 (Table 3).

To further investigate the structure–binding relationships of these heteroaromatic-based benzenesulfonamide derivatives, we conducted a docking study to explore the binding mode of **11k** with the M2 protein of the H5N1 virus. Docking experiments were carried out based on the published M2 protein (PDB: 2KQT)³⁹ with amantadine. AutoDockTool 4.2 (ref. 40) was used to study the binding modes of **11k**, and the results indicated a good binding score ($-5.87 \text{ kcal mol}^{-1}$). As shown in Fig. 5A–C, the 2,5-dimethyl-thiophene moiety of compound **11k** enters into the M2 protein cavity formed by residues Ala-30, Ser-31, Ile-33, Gly-34 and Ile-35, demonstrating that the 2,5-dimethyl-thiophene moiety played a significant role in the anti-influenza activity. Moreover, one oxygen atom of the sulfonamide moiety formed a hydrogen bond with the backbone residue His-37, and the nitrogen atom of the sulfonamide moiety formed another hydrogen bond with residue Gly-34, verifying that the sulfonamide moiety is necessary in this series of compounds (Fig. 5B–D).

Fig. 4 Results of the time-course experiment. Compound **11k** ($c = 0.68 \text{ } \mu\text{g mL}^{-1}$), AMD (amantadine, $c = 0.26 \text{ } \mu\text{g mL}^{-1}$) and T-705 (favipiravir, $c = 0.63 \text{ } \mu\text{g mL}^{-1}$) were added to MDCK cells that had been infected with H5N1 virus at an MOI of 2 at the indicated time.

Table 3 Growth restoration in yeast expressing WT and mutant M2 by heteroaromatic-based benzenesulfonamide derivatives

Entry	Cmpd	EC ₅₀ ^a (μM) WT M2	EC ₅₀ (μM) V27A/S31N M2	Yeast toxicity ^c
1	11a	1.71 ± 0.64	NA ^b	>215.9
2	11b	12.74 ± 5.51	NA	168.8 ± 34.4
3	11c	24.00 ± 7.06	NA	>236.5
4	11d	3.07 ± 1.00	NA	123.43 ± 16.68
5	11e	4.65 ± 0.87	NA	72.6 ± 11.6
6	11f	81.48 ± 21.25	NA	>237.4
7	11g	2.21 ± 0.92	NA	>205.3
8	11h	1.40 ± 0.33	NA	>218.7
9	11i	NA	NA	120.2 ± 26.7
10	11j	1.08 ± 0.32	NA	114.1 ± 22.2
11	11k	1.58 ± 0.56	NA	133.2 ± 19.4
12	11l	2.38 ± 0.67	NA	>224.6
13	11m	2.01 ± 0.67	NA	157.5 ± 20.1
14	11n	NA	NA	>201.3
15	12a	3.44 ± 1.15	NA	>192.3
16	12b	45.67 ± 15.22	NA	>204.0
17	12c	6.22 ± 2.18	NA	133.8 ± 24.9
18	12d	5.33 ± 1.77	NA	121.4 ± 20.7
19	12e	15.25 ± 5.26	NA	134.1 ± 23.7
20	12f	NA	NA	>180.4
21	12g	22.68 ± 6.30	NA	>211.08
22	12h	NA	NA	59.1 ± 12.4
23	12i	NA	NA	>208.5
24	12j	27.79 ± 11.58	NA	>194.0
25	12k	NA	NA	>192.3
26	12l	NA	NA	>204.0
27	12m	NA	NA	>208.5
28	12n	NA	NA	>198.3
29	12o	NA	NA	>176.2
30	12p	NA	NA	>180.4
31	12q	NA	NA	>211.08
32	12r	NA	NA	>180.5
33	12s	NA	NA	>180.5
34	Amantadine	0.66 ± 0.20	NA	>443.0
35	Oseltamivir phosphate	NA	NA	>214.5

^a EC₅₀: concentration that effectively inhibited the expression of M2 protein by 50%. ^b NA: denotes inactive at the highest concentration tested.

^c Yeast toxicity: concentration that inhibited the proliferation of the control yeast strain by 50%.

Conclusions

In summary, we have designed and synthesized a novel series of heteroaromatic-based benzenesulfonamide derivatives as M2 proton channel inhibitors. Several of the synthesized compounds show sub-micromolar activity against amantadine-sensitive H5N1 virus and low cytotoxicity in MDCK cells. The SAR investigation and molecular docking results indicated that the 2,5-dimethylthiophene core structure and sulfonamide moiety played key roles in the inhibition activity. Among the synthesized compounds, 11k is the most effective derivative with an EC₅₀ value of 0.47 μM and selectivity index of 119.98, which are comparable with those of reference drugs amantadine and oseltamivir phosphate. A further mechanistic investigation of these potent M2 inhibitors is underway and will be reported in due course.

Experimental section

Materials and methods

Reagents and materials were obtained from commercial suppliers unless otherwise noted. Reactions were monitored by

thin layer chromatography. Column chromatography purification was performed using 230–400-mesh silica gel. NMR spectra were measured on Bruker DRX and DMX spectrometers at 400 MHz for ¹H spectra and 100 MHz for ¹³C spectra. Spectra were calibrated using the residual solvent signal. All final products were characterized by ¹H NMR, ¹³C NMR and MS analyses.

Representative procedure for the synthesis of 2,5-dimethylfuran-3-carboxamide 8a

Thionyl chloride (0.14 mL, 1.872 mmol) was added to a solution of 2,5-dimethylfuran-3-carboxylic acid 6a (174.8 mg, 1.248 mmol) in toluene (5 mL), and the mixture was heated under reflux for 2 h. After the reaction was completed, the solution was concentrated. Without further purification, the crude product 2,5-dimethylfuran-3-carbonyl chloride (7a) was immediately used in the next step. Ammonium hydroxide (25% aqueous solution, 1 mL) was then added dropwise to a solution of intermediate 7a in anhydrous dichloromethane (5 mL) at 0 °C. The mixture was stirred at room temperature for

Fig. 5 (A) The solid surface type between **11k** with M2 protein (oxygen atoms are shown in red, sulfur atoms are shown in yellowish orange, and nitrogen atoms are shown in blue). (B) The transparent surface type between **11k** with M2 protein (same as above). (C) The hydrophobic interactions and hydrogen bond interactions formed between **11k** with the backbone residues of M2 protein. (D) Computer modeling of the complex structures of M2 protein with **11k** based on the published structure (PDB: 2KQT) of M2 protein with amantadine.

1 h. The mixture was then extracted with ethyl acetate (3×30 mL) and brine, dried over anhydrous sodium sulfate, and concentrated by vacuum pump. The residue was purified by flash column chromatography and eluted with petroleum ether/ethyl acetate (2:1) to produce the 2,5-dimethylfuran-3-carboxamide (**8a**) as a white solid.

Representative procedure for the synthesis of *N*-((2,5-dimethylfuran-3-yl)methyl)-4-nitrobenzenesulfonamide **11a**

Lithium aluminum hydride (128.4 mg, 3.384 mmol) was added to a solution of **8a** (157.0 mg, 1.128 mmol) in anhydrous THF (5 mL) at 0 °C. The solution was warmed to ambient temperature and heated under reflux for 4 h. After completion, the reaction was quenched by the sequential addition of 0.13 mL H₂O, 0.13 mL 5% NaOH solution, and 0.39 mL H₂O. Ethyl acetate was then added to the above mixture followed by stirring at room temperature for 30 min. Next, the filtrate was dried over anhydrous sodium sulfate and concentrated by vacuum pump. Without further purification, the crude (2,5-dimethylfuran-3-yl)methanamine **9a** was directly used in the next step. Triethylamine (0.19 mL, 1.354 mmol) was added to a solution of the key amine intermediate **9a** (141.2 mg, 1.128 mmol) in anhydrous dichloromethane at 0 °C followed by the

addition of 4-nitrobenzene-sulfonyl chloride **10a** (275.0 mg, 1.241 mmol). The mixture was stirred at room temperature for 5 h. After concentration under vacuum pump, the residue was purified by flash column chromatography and eluted with petroleum ether/ethyl acetate (10:1) to produce *N*-((2,5-dimethylfuran-3-yl)methyl)-4-nitrobenzenesulfonamide **11a** in 40% yield as a yellow solid: mp 127–129 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.35–8.30 (m, 2H), 8.01–7.96 (m, 2H), 5.61 (s, 1H), 4.95 (t, J = 5.4 Hz, 1H), 3.95 (d, J = 5.6 Hz, 2H), 2.10 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 150.48, 149.92, 147.64, 146.18, 128.29, 124.15, 114.42, 106.18, 38.59, 13.23, 11.34. HRMS (ESI) calcd for C₁₃H₁₄N₂O₅S [M + Na]⁺ 333.0521, found 333.0520.

4-Cyano-*N*-((2,5-dimethylfuran-3-yl)methyl)-benzenesulfonamide **11b.** 51% yield as a white solid, mp 115–117 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.95–7.88 (m, 2H), 7.81–7.75 (m, 2H), 5.60 (s, 1H), 4.92 (t, J = 5.5 Hz, 1H), 3.93 (d, J = 5.6 Hz, 2H), 2.14 (s, 3H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 150.41, 147.59, 144.60, 132.74, 127.67, 117.38, 116.13, 114.45, 106.21, 38.53, 13.28, 11.34. HRMS (ESI) calcd for C₁₄H₁₄N₂O₃S [M + Na]⁺ 313.0623, found 313.0617.

***N*-((2,5-Dimethylfuran-3-yl)methyl)-4-fluorobenzenesulfonamide **11c**.** 41% yield as brown solid, mp 81–83 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.92–7.73 (m, 2H), 7.27–7.14 (m, 2H), 5.64 (s, 1H), 4.86 (t, J = 5.3 Hz, 1H), 3.87 (d, J =

5.6 Hz, 2H), 2.13 (s, 3H), 2.07 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.28, 163.75, 150.21, 147.43, 136.18, 129.87, 116.26, 116.03, 114.70, 106.37, 38.41, 13.26, 11.28. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{FNO}_3\text{S}$ $[\text{M} + \text{Na}]^+$ 306.0576, found 306.0573.

4-Chloro-N-((2,5-dimethylfuran-3-yl)methyl)benzenesulfonamide 11d. 48% yield as grey solid, mp 85–87 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.7 Hz, 2H), 5.62 (s, 1H), 4.81 (t, J = 5.5 Hz, 1H), 3.86 (d, J = 5.6 Hz, 2H), 2.12 (s, 3H), 2.08 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 150.27, 147.46, 139.03, 138.66, 129.22, 128.57, 114.64, 106.33, 38.45, 13.27, 11.31. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{ClNO}_3\text{S}$ $[\text{M} + \text{Na}]^+$ 322.0281, found 322.0277.

4-Bromo-N-((2,5-dimethylfuran-3-yl)methyl)benzenesulfonamide 11e. 51% yield as a brown solid, mp 103–105 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 8.6 Hz, 2H), 5.62 (s, 1H), 4.83 (t, J = 5.5 Hz, 1H), 3.87 (d, J = 5.7 Hz, 2H), 2.13 (s, 3H), 2.09 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 150.28, 147.46, 139.20, 132.21, 128.65, 127.48, 114.62, 106.32, 38.45, 13.29, 11.32. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{BrNO}_3\text{S}$ $[\text{M} + \text{Na}]^+$ 365.9775, found 365.9773.

N-(Furan-3-ylmethyl)-4-nitrobenzenesulfonamide 11f. 28% yield as a white solid, mp 120–122 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.41 (d, J = 8.8 Hz, 2H), 8.15–8.05 (m, 2H), 7.46–7.36 (m, 2H), 7.21 (s, 1H), 6.32 (s, 1H), 4.12 (d, J = 6.1 Hz, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 149.97, 146.89, 143.51, 140.55, 128.40, 124.23, 121.46, 110.11, 37.92. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_5\text{S}$ $[\text{M} + \text{Na}]^+$ 305.0208, found 305.0205.

N-[(2,5-Dimethylthiophen-3-yl)methyl]-4-nitrobenzenesulfonamide 11g. 41% yield as a yellow solid, mp 134–136 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.28 (d, J = 8.7 Hz, 2H), 7.93 (d, J = 8.7 Hz, 2H), 6.28 (s, 1H), 5.18 (t, J = 5.4 Hz, 1H), 4.06 (d, J = 5.6 Hz, 2H), 2.23 (d, J = 2.2 Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 149.83, 146.08, 136.62, 134.62, 130.77, 128.16, 125.91, 124.07, 40.30, 14.89, 12.65. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 349.0293, found 349.0285.

N-[(2,5-Dimethylthiophen-3-yl)methyl]-4-cyanobenzenesulfonamide 11h. 60% yield as a white solid, mp 108–110 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.90–7.80 (m, 2H), 7.75–7.68 (m, 2H), 6.26 (s, 1H), 5.39 (t, J = 5.7 Hz, 1H), 4.02 (d, J = 5.7 Hz, 2H), 2.25 (s, 3H), 2.21 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 144.54, 136.65, 134.61, 132.68, 130.72, 127.56, 125.84, 117.37, 116.08, 40.30, 14.94, 12.65. HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 329.0394, found 329.0389.

N-[(2,5-Dimethylthiophen-3-yl)methyl]-4-fluorobenzenesulfonamide 11i. 43% yield as a grey solid, mp 87–89 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.92–7.73 (m, 2H), 7.22–7.09 (m, 2H), 6.32 (s, 1H), 4.76 (t, J = 5.5 Hz, 1H), 3.98 (d, J = 5.7 Hz, 2H), 2.29 (s, 3H), 2.21 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 66.27, 163.74, 136.42, 136.09, 134.32, 131.05, 129.82, 125.99, 116.26, 116.04, 40.24, 14.94, 12.60. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 322.0348, found 322.0344.

N-[(2,5-Dimethylthiophen-3-yl)methyl]-4-chlorobenzenesulfonamide 11j. 41% yield as a grey solid, mp 98–

100 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, J = 8.6 Hz, 2H), 7.43 (d, J = 8.6 Hz, 2H), 6.29 (s, 1H), 4.97 (t, J = 5.6 Hz, 1H), 3.97 (d, J = 5.7 Hz, 2H), 2.27 (s, 3H), 2.21 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 138.97, 138.60, 136.38, 134.31, 131.04, 129.20, 128.48, 126.01, 40.23, 14.94, 12.63. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{ClNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 338.0052, found 338.0048.

N-[(2,5-Dimethylthiophen-3-yl)methyl]-4-bromobenzenesulfonamide 11k. 53% yield as a white solid, mp 119–121 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.72–7.54 (m, 4H), 6.29 (s, 1H), 4.71 (t, J = 5.4 Hz, 1H), 3.98 (d, J = 5.6 Hz, 2H), 2.29 (s, 3H), 2.22 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 139.15, 136.48, 134.38, 132.21, 130.96, 128.58, 127.47, 125.94, 40.26, 14.97, 12.64. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{BrNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 381.9547, found 381.9543.

4-Nitro-N-(thiophen-3-ylmethyl)benzenesulfonamide 11l. 52% yield as a white solid, mp 131–133 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (d, J = 5.3 Hz, 2H), 7.99 (d, J = 4.9 Hz, 2H), 7.23 (d, J = 2.0 Hz, 1H), 7.09 (s, 1H), 6.87 (d, J = 3.7 Hz, 1H), 5.12 (t, J = 5.9 Hz, 1H), 4.28 (d, J = 5.7 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 149.99, 146.05, 136.43, 128.26, 127.00, 126.87, 124.29, 123.46, 42.48. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 320.9980, found 320.9975.

4-Nitro-N-(thiophen-2-ylmethyl)benzenesulfonamide 11m. 36% yield as a white solid, mp 154–156 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (d, J = 8.8 Hz, 2H), 8.00 (d, J = 8.9 Hz, 2H), 7.20–7.13 (m, 2H), 6.91–6.82 (m, 2H), 5.09 (t, J = 5.6 Hz, 1H), 4.47 (d, J = 5.4 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 150.00, 146.05, 138.20, 128.34, 127.14, 127.00, 126.38, 124.32, 42.17. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 320.9980, found 320.9980.

N-[(5-Chlorothiophen-2-yl)methyl]-4-nitrobenzenesulfonamide 11n. 60% yield as a white solid, mp 118–120 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.48–8.29 (m, 2H), 8.10 (dd, J = 8.8, 2.1 Hz, 2H), 7.64–7.45 (m, 1H), 7.31 (dd, J = 5.1, 1.1 Hz, 1H), 6.89 (m, 1H), 6.80 (s, 1H), 4.46 (d, J = 6.1 Hz, 1H), 4.41 (d, J = 6.2 Hz, 1H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 146.93, 139.87, 128.40, 128.35, 126.63, 126.33, 126.07, 125.73, 124.29, 41.68. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 320.9980, found 320.9980.

N-(1-Benzothiophen-3-ylmethyl)-4-nitrobenzenesulfonamide 12a. 35% yield as a white solid, mp 114–116 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.32–8.28 (m, 2H), 8.12–8.06 (m, 2H), 7.80 (d, J = 7.2 Hz, 1H), 7.70 (d, J = 7.1 Hz, 1H), 7.64 (s, 1H), 7.34–7.25 (m, 2H), 7.20 (d, J = 0.6 Hz, 1H), 4.56 (d, J = 5.8 Hz, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 146.44, 140.31, 137.56, 131.50, 128.03, 125.65, 124.07, 123.76, 122.51, 121.87, 40.86. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 371.0136, found 371.0131.

N-(1-Benzothiophen-3-ylmethyl)-4-cyanobenzenesulfonamide 12b. 28% yield, semi-solid. ^1H NMR (400 MHz, Acetone- d_6) δ 7.94 (d, J = 8.5 Hz, 2H), 7.89–7.83 (m, 4H), 7.49 (s, 1H), 7.39–7.35 (m, 3H), 4.50 (d, J = 6.1 Hz, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 144.96, 140.38, 137.66, 132.69, 131.55, 127.45, 125.55, 124.54, 124.11, 122.64, 121.92, 117.39, 115.33, 40.91. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 351.0238, found 351.0234.

***N*-(1-Benzothiophen-3-ylmethyl)-4-fluorobenzenesulfonamide 12c.** 36% yield, semi-solid. ^1H NMR (400 MHz, CDCl_3) δ 7.88–7.75 (m, 3H), 7.70–7.63 (m, 1H), 7.36–7.34 (m, 2H), 7.24 (s, 1H), 7.11–7.07 (m, 2H), 4.97 (t, J = 5.5 Hz, 1H), 4.39 (d, J = 5.6 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.27, 163.74, 140.53, 137.21, 130.34, 129.81, 129.72, 125.40, 124.81, 124.43, 122.92, 121.56, 116.34, 116.11, 41.36. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0187.

***N*-(1-Benzothiophen-3-ylmethyl)-4-chlorobenzenesulfonamide 12d.** 29% yield as a yellow solid, mp 130–132 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.74–7.71 (m, 1H), 7.66–7.62 (m, 2H), 7.60–7.56 (m, 1H), 7.32–7.30 (m, 1H), 7.29–7.26 (m, 3H), 7.16 (s, 1H), 4.91 (t, J = 5.8 Hz, 1H), 4.32 (d, J = 5.3 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.50, 139.15, 138.07, 137.14, 130.23, 129.24, 128.44, 125.46, 124.80, 124.41, 122.92, 121.50, 41.36. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{ClNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 359.9896, found 359.9891.

***N*-(1-Benzothiophen-3-ylmethyl)-4-bromobenzenesulfonamide 12e.** 28% yield as a yellow solid, mp 138–140 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.81–7.79 (m, 1H), 7.68–7.61 (m, 3H), 7.53 (d, J = 8.6 Hz, 2H), 7.37–7.33 (m, 2H), 7.23 (s, 1H), 5.00 (t, J = 5.7 Hz, 1H), 4.39 (d, J = 5.8 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.53, 138.64, 137.17, 132.21, 130.28, 128.51, 127.63, 125.51, 124.81, 124.43, 122.95, 121.53, 41.36. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{BrNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 403.9391, found 403.9388.

***N*-(1-Benzothiophen-3-ylmethyl)-4-(trifluoromethyl)benzenesulfonamide 12f.** 36% yield, semi-solid. ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.80–7.70 (m, 1H), 7.67–7.55 (m, 3H), 7.36–7.30 (m, 2H), 7.25 (d, J = 7.4 Hz, 1H), 5.18 (t, J = 5.5 Hz, 1H), 4.44 (d, J = 5.7 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 143.16, 140.48, 137.08, 130.09, 127.38, 125.94, 125.91, 125.82, 124.83, 124.42, 122.93, 121.41, 41.39. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{12}\text{F}_3\text{NO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 394.0159, found 394.0157.

***N*-(1-Benzothiophen-3-ylmethyl)-4-methylbenzenesulfonamide 12g.** 29% yield as a white solid, mp 158–160 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 7.82–7.78 (m, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.68–7.66 (m, 1H), 7.35–7.32 (m, 2H), 7.26–7.21 (m, 4H), 4.93 (t, J = 5.9 Hz, 1H), 4.35 (d, J = 6.0 Hz, 2H), 2.41 (s, 3H). ^{13}C (100 MHz, Acetone- d_6) δ 143.64, 140.54, 137.32, 136.48, 130.64, 129.74, 127.18, 125.11, 124.73, 124.38, 122.86, 121.70, 41.40, 21.58. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 340.0442, found 340.0438.

***N*-(1-Benzothiophen-3-ylmethyl)-2-fluorobenzenesulfonamide 12h.** 33% yield as a grey solid, mp 197–199 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.77 (m, 1H), 7.70–7.65 (m, 1H), 7.61–7.58 (m, 1H), 7.54–7.50 (m, 1H), 7.45–7.39 (m, 1H), 7.37–7.31 (m, 2H), 7.25–7.19 (m, 2H), 4.99 (t, J = 5.7 Hz, 1H), 4.45–4.39 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.60, 161.10, 141.73, 140.54, 137.20, 130.89, 130.29, 125.49, 124.82, 124.45, 122.90, 121.52, 120.02, 114.58, 41.40. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0188.

***N*-(1-Benzothiophen-3-ylmethyl)-3-fluorobenzenesulfonamide 12i.** 27% yield as white solid, mp 104–

106 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.81–7.76 (m, 1H), 7.68–7.64 (m, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.37–7.32 (m, 3H), 7.22–7.18 (m, 2H), 5.15 (s, 1H), 4.39 (d, J = 5.4 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.65, 161.15, 141.85, 139.88, 139.41, 139.15, 130.98, 124.68, 123.59, 123.30, 122.91, 122.36, 120.16, 114.69, 42.97. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0190.

4-Acetyl-*N*-(1-benzothiophen-3-ylmethyl)benzenesulfonamide 12j. 35% yield as a white solid, mp 174–176 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, J = 8.3 Hz, 2H), 7.87 (d, J = 8.3 Hz, 2H), 7.79–7.77 (m, 1H), 7.68–7.64 (m, 1H), 7.35–7.32 (m, 2H), 7.24 (s, 1H), 5.10 (t, J = 5.5 Hz, 1H), 4.43 (d, J = 5.8 Hz, 2H), 2.63 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 196.83, 143.51, 140.52, 139.79, 137.15, 130.24, 128.76, 127.27, 125.62, 124.81, 124.44, 122.87, 121.52, 41.42, 26.93. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{15}\text{NO}_3\text{S}_2$ $[\text{M} + \text{Na}]^+$ 368.0391, found 368.0388.

***N*-(1-Benzothiophen-2-ylmethyl)-4-nitrobenzenesulfonamide 12k.** 52% yield as a white solid, mp 165–166 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.08 (d, J = 8.2 Hz, 2H), 7.86 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 7.2 Hz, 1H), 7.72 (dd, J = 6.7, 2.0 Hz, 1H), 7.52 (m, 1H), 7.32–7.27 (m, 2H), 7.21 (s, 1H), 4.54 (d, J = 6.0 Hz, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 141.87, 140.78, 140.32, 130.60, 129.29, 125.33, 124.98, 124.34, 124.15, 123.07, 43.40. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_4\text{S}_2$ $[\text{M} + \text{Na}]^+$ 371.0136, found 371.0136.

***N*-(1-Benzothiophen-2-ylmethyl)-4-cyanobenzenesulfonamide 12l.** 42% yield as a white solid, mp 144–146 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.04 (d, J = 8.1 Hz, 2H), 7.91 (d, J = 8.7 Hz, 2H), 7.83 (d, J = 7.1 Hz, 1H), 7.73 (d, J = 7.0 Hz, 1H), 7.59 (s, 1H), 7.38–7.29 (m, 2H), 7.21 (s, 1H), 4.55 (d, J = 5.6 Hz, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 146.11, 142.02, 140.79, 140.36, 133.80, 128.58, 125.34, 125.31, 124.35, 124.01, 123.09, 118.23, 116.50, 43.38. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 351.0238, found 351.0233.

***N*-(1-Benzothiophen-2-ylmethyl)-4-fluorobenzenesulfonamide 12m.** 50% yield as a white solid, mp 149–151 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.80–7.75 (m, 2H), 7.75–7.71 (m, 1H), 7.67–7.63 (m, 1H), 7.43–7.37 (m, 2H), 7.36–7.27 (m, 2H), 7.07 (s, 1H), 5.11 (t, J = 6.0 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.42, 139.87, 139.55, 139.16, 129.97, 129.37, 128.60, 124.69, 124.59, 123.56, 123.23, 122.36, 116.45, 116.22, 42.91. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0187.

***N*-(1-Benzothiophen-2-ylmethyl)-4-chlorobenzenesulfonamide 12n.** 46% yield as white solid, mp 171–173 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.88–7.83 (m, 1H), 7.78–7.72 (m, 2H), 7.68–7.61 (m, 1H), 7.39 (d, J = 8.6 Hz, 1H), 7.35–7.27 (m, 2H), 7.12–7.06 (m, 2H), 5.19–5.08 (m, 1H), 4.44 (d, J = 6.0 Hz, 2H). ^{13}C NMR (400 MHz, CDCl_3) δ 139.87, 139.60, 139.17, 129.95, 129.86, 129.36, 128.59, 124.67, 124.57, 123.56, 123.22, 122.35, 116.43, 116.21, 42.89. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{ClNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 359.9896, found 359.9892.

***N*-(1-Benzothiophen-2-ylmethyl)-4-bromobenzenesulfonamide 12o.** 53% yield as a white solid, mp 194–196 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 7.86–7.79 (m,

3H), 7.73–7.71 (m, 3H), 7.37–7.28 (m, 3H), 7.22 (s, 1H), 4.47 (d, $J = 5.6$, 2H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 142.36, 141.26, 140.79, 140.46, 133.08, 129.75, 127.43, 125.25, 125.23, 124.31, 123.68, 123.10, 43.41. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{BrNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 403.9391, found 403.9388.

***N*-(1-Benzothiophen-2-ylmethyl)-4-(trifluoromethyl)-benzene-sulfonamide 12p.** 35% yield as a white solid, mp 178–180 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 8.08 (d, $J = 8.2$ Hz, 2H), 7.87 (d, $J = 8.3$ Hz, 2H), 7.83–7.79 (m, 1H), 7.72 (dd, $J = 6.7$, 2.1 Hz, 1H), 7.53 (t, $J = 6.1$ Hz, 1H), 7.37–7.27 (m, 2H), 7.22 (s, 1H), 4.64–4.45 (m, 1H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 141.23, 139.88, 139.48, 127.78, 126.10, 126.06, 124.35, 123.40, 122.99, 122.14, 42.50. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{12}\text{F}_3\text{NO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 394.0159, found 394.0156.

***N*-(1-Benzothiophen-2-ylmethyl)-4-methylbenzenesulfonamide 12q.** 40% yield as a white solid, mp 174–176 °C. ^1H NMR (400 MHz, Acetone- d_6) δ 7.78–7.73 (m, 3H), 7.65 (dd, $J = 6.7$, 2.0 Hz, 1H), 7.34–7.27 (m, 3H), 7.07 (s, 1H), 4.80 (t, $J = 5.8$ Hz, 1H), 4.43 (d, $J = 5.8$ Hz, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, Acetone- d_6) δ 139.76, 129.77, 127.26, 124.55, 124.49, 123.52, 123.03, 122.36, 42.97, 21.56. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 340.0442, found 340.0438.

***N*-(1-Benzothiophen-2-ylmethyl)-2-fluorobenzenesulfonamide 12r.** 49% yield as a white solid, mp 120–122 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.8$ Hz, 2H), 7.98 (d, $J = 8.8$ Hz, 2H), 7.23–7.16 (m, 1H), 7.08 (d, $J = 1.9$ Hz, 1H), 6.86–6.80 (m, 1H), 5.10 (s, 1H), 4.26 (d, $J = 5.7$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.55, 139.92, 139.35, 139.22, 135.07, 130.24, 124.60, 124.49, 124.33, 123.55, 123.30, 122.31, 117.00, 116.79, 42.97. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0187.

***N*-(1-Benzothiophen-2-ylmethyl)-3-fluorobenzenesulfonamide 12s.** 36% yield as a white solid, mp 106–108 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 7.4$ Hz, 1H), 7.66 (d, $J = 7.1$ Hz, 2H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.47–7.42 (m, 1H), 7.37–7.21 (m, 3H), 7.10 (s, 1H), 5.01 (t, $J = 5.6$, 1H), 4.47 (d, $J = 6.1$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.65, 161.15, 141.85, 139.88, 139.41, 139.15, 130.98, 124.68, 123.59, 123.30, 122.91, 122.36, 120.16, 114.69, 114.45, 42.97. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2\text{S}_2$ $[\text{M} + \text{Na}]^+$ 344.0191, found 344.0189.

Plaque reduction assay

The sequence of the M2 protein of amantadine-sensitive H5N1 virus [A/chicken/Hubei/327/2004 (H5N1)] is MSLLEVEPTPRTNEWECRCSDSSDPLVVAASIIIGLHLILWLDRLFFKCIYRRLKYGLKRGPTAGVPESMREEYRQEQQSAVDVDDGHFVNIELE. Amantadine-resistant H5N1 virus was obtained by screening amantadine-resistant H5N1 flu strains based on amantadine-sensitive H5N1 virus [A/chicken/Hubei/327/2004 (H5N1)]. We confirmed that the mutation site of the M2 protein of amantadine-resistant H5N1 virus was M2-S31 N by sequencing M2 protein. M2-S31N is the most common amantadine-resistant mutation site among isolated influenza A viruses (H5N1, H1N1, etc.).

MDCK (Madin–Darby canine kidney) cells were purchased from the American Type Culture Collection. A confluent monolayer of MDCK cells was prepared in six-well plates. The cells were infected with amantadine-sensitive H5N1 virus [A/chicken/Hubei/327/2004 (H5N1)] and amantadine-resistant H5N1 virus at 100 PFU per well in DMEM supplemented with 0.001% DEAE-dextran, 2 mg mL^{-1} TPCK-treated trypsin, and 0.5% agarose in the presence of various concentrations of test compounds for 40 min at 37 °C. Medium containing 0.001% DEAE-dextran, 2 mg mL^{-1} TPCK-treated trypsin, 0.5% agarose and test compounds at the same concentrations was then added. After 2–3 days of incubation at 37 °C in a CO_2 incubator, cell monolayers were fixed with 3% formaldehyde and stained with 0.5% crystal violet, and the EC_{50} values were determined. Amantadine was included in all experiments as a reference compound.

Cytotoxicity assay

The cytotoxicities of compounds in MDCK cells were tested using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Briefly, cells were seeded at a density of 2×10^4 per well into 96-well plates. The next day, the cell medium was removed, and fresh media containing DMEM plus test compounds at various concentrations were added to each well. After 24 h, 5 mg mL^{-1} MTT solution was added to each well, and the plates were incubated for 4 h at 37 °C in a CO_2 incubator. Successively, a solubilization solution was added to lyse the cells. After 3 h of incubation at 37 °C, absorbance was measured at 575 nm using an ELISA plate reader (Tecan Sunrise).

Time-of-addition assay

MDCK cells were seeded in 48-well plates and infected with amantadine-sensitive H5N1 virus at an MOI of 2. Compound 11k and AMD were added at the time of infection (0 h) and at 1, 2, 3, 4, 6 and 8 h after infection. Viral titers were determined at 12 h after infection by plaque assay as described above. Compound 11k was added at a concentration of 1.9 μM . T-705 (4.0 μM) and AMD (1.7 μM) were used as control treatments.

Determination of M2 inhibitory activity by yeast growth restoration assay

The coding sequences of the wild-type, V27A/S31N-mutated M2 gene from the H5N1 strain [A/chicken/Hubei/327/2004(H5N1)] were introduced downstream of the GAL1 promoter by PCR amplification followed by recombination cloning in yeast.³⁵ Plasmids were rescued from the yeast strains, and the coding sequences were verified. The yeast strains were propagated in synthetic complete (SC) medium (pH 6.5) lacking leucine and containing glucose to repress M2 gene expression. After harvesting the yeast by centrifugation, the pellets were washed with water to remove traces of glucose and then suspended to $\text{A}_{600} = 0.01$ in liquid SC medium (pH 6.5) lacking leucine and containing 2% galactose. Samples

(100 μ L) were distributed into 96-well plates. The compounds were transferred to the yeast plates at different concentrations, and the plates were incubated at 30 °C in a humidified incubator. After 46–48 h, the cells were suspended by vortexing, and A600 was measured. The percentage of growth restoration was calculated as described previously.³⁶ Compounds leading to growth restoration were retested in triplicate at different concentrations against WT M2, V27A/S31N M2 and empty plasmid strains to confirm their activity and determine EC₅₀.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful to the NSFC (81772236, 81773557 and 81573279), Major Project of Technology Innovation Program of Hubei Province (2016ACA126, 2018ACA123), NSFHP (2017CFA024), the Fundamental Research Funds for the Central Universities of China (2042017kf0288), and Open Research Fund Program of the Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals for support of this research.

Notes and references

- E. J. Schrauwen and R. A. Fouchier, *Emerging Microbes Infect.*, 2014, **3**, e9.
- X. Wu, X. Wu, Q. Sun, C. Zhang, S. Yang, L. Li and Z. Jia, *Theranostics*, 2017, **7**, 826–845.
- C. Paules and K. Subbarao, *Lancet*, 2017, **390**, 697–708.
- J. K. Taubenberger and D. M. Morens, *Emerging Infect. Dis.*, 2006, **12**, 15–22.
- C. Scholtissek, W. Rohde, V. Von Hoyningen and R. Rott, *Virology*, 1978, **87**, 13–20.
- G. J. D. Smith, D. Vijaykrishna, J. Bahl, S. J. Lycett, M. Worobey, O. G. Pybus, S. K. Ma, C. L. Cheung, J. Raghvani, S. Bhatt, J. S. M. Peiris, Y. Guan and A. Rambaut, *Nature*, 2009, **459**, 1122–1125.
- V. N. Petrova and C. A. Russell, *Nat. Rev. Microbiol.*, 2018, **16**, 47–60.
- K. Das, *J. Med. Chem.*, 2012, **55**, 6263–6277.
- M. Biggerstaff, S. Cauchemez, C. Reed, M. Gambhir and L. Finelli, *BMC Infect. Dis.*, 2014, **14**, 480.
- N. P. A. S. Johnson and J. Mueller, *Bull. Hist. Med.*, 2002, **76**, 105–115.
- P. Palese, *Nat. Med.*, 2004, **10**, S82–S87.
- A. N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F. G. Hayden, D. H. Nguyen, M. D. de Jong, A. Naghdaliyev, J. S. M. Peiris, N. Shindo, S. Soerose and T. M. Uyeki, *N. Engl. J. Med.*, 2008, **358**, 261–273.
- L. Fiebig, J. Soyka, S. Buda, U. Buchholz, M. Dehnert and W. Haas, *Euro. Surveill.*, 2011, **16**, 19941.
- Y. Guan, L. L. M. Poon, C. Y. Cheung, T. M. Ellis, W. Lim, A. S. Lipatov, K. H. Chan, K. M. Sturm-Ramirez, C. L. Cheung, Y. H. C. Leung, K. Y. Yuen, R. G. Webster and J. S. M. Peiris, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 8156–8161.
- J. Yin, S. Liu and Y. Zhu, *Viol. Sin.*, 2013, **28**, 3–15.
- H. Yu, B. J. Cowling, L. Feng, E. H. Y. Lau, Q. Liao, T. K. Tsang, Z. Peng, P. Wu, F. Liu, V. J. Fang, H. Zhang, M. Li, L. Zeng, Z. Xu, Z. Li, H. Luo, Q. Li, Z. Feng, B. Cao, W. Yang, J. T. Wu, Y. Wang and G. M. Leung, *Lancet*, 2013, **382**, 138–145.
- D. Xiang, X. Shen, Z. Pu, D. M. Irwin, M. Liao and Y. Shen, *J. Infect. Dis.*, 2018, **217**, 1699–1707.
- M. von Itzstein, *Nat. Rev. Drug Discovery*, 2007, **6**, 967–974.
- K. K. W. To, K. H. L. Ng, T.-L. Que, J. M. C. Chan, K.-Y. Tsang, A. K. L. Tsang, H. Chen and K.-Y. Yuen, *Emerg. Microbes Infect.*, 2012, **1**, e25.
- G. Neumann, *Future Virol.*, 2015, **10**, 971–980.
- P. J. Collins, L. F. Haire, Y. P. Lin, J. Liu, R. J. Russell, P. A. Walker, J. J. Skehel, S. R. Martin, A. J. Hay and S. J. Gamblin, *Nature*, 2008, **453**, 1258–1261.
- H. Leonov, P. Astrahan, M. Krugliak and I. T. Arkin, *J. Am. Chem. Soc.*, 2011, **133**, 9903–9911.
- E. A. Govorkova, T. Baranovich, P. Seiler, J. Armstrong, A. Burnham, Y. Guan, M. Peiris, R. J. Webby and R. G. Webster, *Antiviral Res.*, 2013, **98**, 297–304.
- A. Jacob, R. Sood, K. V. Chanu, S. Bhatia, R. Khandia, A. K. Pateriya, S. Nagarajan, U. Dimri and D. D. Kulkarni, *Microb. Pathog.*, 2016, **91**, 35–40.
- A. M. Joseph, C. Xi, B. J. Colleen, A. Subramaniam, H. Judith, F. S. Donald, W. N. James, N. Diana, X. Xiaolin, J. Fuli, M. Clinton, I. S. Melinda, E. L. White and E. S. William, *J. Biomol. Screening*, 2010, **16**, 73–81.
- S. Liu, R. Li, R. Zhang, C. C. S. Chan, B. Xi, Z. Zhu, J. Yang, V. K. M. Poon, J. Zhou, M. Chen, J. Münch, F. Kirchhoff, S. Pleschka, T. Haarmann, U. Dietrich, C. Pan, L. Du, S. Jiang and B. Zheng, *Eur. J. Pharmacol.*, 2011, **660**, 460–467.
- J. Yang, J. X. Yang, F. Zhang, G. Chen, W. Pan, R. Yu, S. Wu and P. Tien, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 2680–2684.
- Z. Zhu, Z. Yao, X. Shen, Z. Chen, X. Liu, J. R. Parquette and S. Liu, *Eur. J. Med. Chem.*, 2017, **130**, 185–194.
- Y. Yu, J. Zheng, L. Cao, S. Li, X. Li, H.-B. Zhou, X. Liu, S. Wu and C. Dong, *RSC Adv.*, 2017, **7**, 9620–9627.
- X. Han, H. Wu, W. Wang, C. Dong, P. Tien, S. Wu and H.-B. Zhou, *Org. Biomol. Chem.*, 2014, **12**, 8308–8317.
- X. Han, H. Wu, C. Dong, P. Tien, W. Xie, S. Wu and H.-B. Zhou, *RSC Adv.*, 2015, **5**, 10005–10013.
- J. Pan, X. Han, N. Sun, H. Wu, D. Lin, P. Tien, H.-B. Zhou and S. Wu, *RSC Adv.*, 2015, **5**, 55100–55108.
- X. Han, N. Sun, H. Wu, D. Guo, P. Tien, C. Dong, S. Wu and H.-B. Zhou, *J. Med. Chem.*, 2016, **59**, 2139–2150.
- L. H. Pinto and R. A. Lamb, *J. Biol. Chem.*, 2006, **281**, 8997–9000.
- S. Kurtz, G. Luo, K. M. Hahnenberger, C. Brooks, O. Gecha, K. Ingalls, K. Numata and M. Krystal, *Antimicrob. Agents Chemother.*, 1995, **39**, 2204–2209.

- 36 A. D. Balgi and M. Roberge, *Methods Mol. Biol.*, 2009, **486**, 125–137.
- 37 A. D. Balgi, J. Wang, D. Y. H. Cheng, C. Ma, T. A. Pfeifer, Y. Shimizu, H. J. Anderson, L. H. Pinto, R. A. Lamb, W. F. DeGrado and M. Roberge, *PLoS One*, 2013, **8**, e55271.
- 38 A. S. Arns, A. D. Balgi, Y. Shimizu, T. A. Pfeifer, N. Kumar, F. S. Shidmoossavee, S. Sun, S. S. H. Tai, O. Agafitei, J. B. Jaquith, E. Bourque, M. Niikura and M. Roberge, *Eur. J. Med. Chem.*, 2016, **120**, 64–73.
- 39 Y. Wu, B. Canturk, H. Jo, C. Ma, E. Gianti, M. L. Klein, L. H. Pinto, R. A. Lamb, G. Fiorin, J. Wang and W. F. DeGrado, *J. Am. Chem. Soc.*, 2014, **136**, 17987–17995.
- 40 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.